Browse online courses and resources on Melanoma and Skin Cancers.

All Melanoma & Skin Cancers Courses
Collapse 2018 Webinar Course: Immunotherapy for the Treatment of Melanoma and irAE Management (Advances in Cancer Immunotherapy™)

aci17-sitc-clr.jpg

From the Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) educational series, this course provides an overview on cancer immunotherapy for the treatment of melanoma and immune related adverse event management. The on-demand webinars, hosted by Dr. Lawson (Winship Cancer Institute of Emory University), and Dr. Lutzky (Mount Sinai Medincal Center) and, nurse, Jeanelle King (Mount Sinai Medical Center), gives an update on immunotherapy for the treatment of melanoma and immune related adverse event management. Stay up to date with the most recent clinical recommendations and research by exploring the curated Additional Resources tab. 

 

 

Target Audience

The target audience includes clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians, allied health professionals, other patient care providers, students and patient advocates. The course is designed to help all members of the cancer health care team stay connected with updates in the field of cancer immunotherapy. 

 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

 

Course Available Beginning: February 19, 2019

Original Course Date: January 31, 2019
MORE INFOMORE INFO 2018 Webinar Course: Immunotherapy for the Treatment of Melanoma and irAE Management (Advances in Cancer Immunotherapy™)
Collapse 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for melanoma and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for melanoma and how to identify and manage common side effects of immunotherapy agents.

 

Target Audience
This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

 

Faculty
Isabella Glitza, MD, PhD

Oncologist 

University of Texas MD Anderson Cancer Center

 

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the rationale for common approaches to cancer immunotherapy.
  • Implement cancer immunotherapy treatment for melanoma.
  • Identify the appropriate clinical management of common side effects of immunotherapy agents.

 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

 

 


Continuing Education Information

 

Credit Available: May 1, 2019 - May 1, 2020

 

Approximate Time to Complete:  45 minutes

 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

sitc_log_color.pngPIM_logo.png

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-606-H01-P)

Type of Activity: Knowledge


Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Isabella Glitza, MD, PhD - Research - Bristol Myers Squib


Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.


Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 24, 2019 through April 24, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

  1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
  2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
  3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
  4. Complete the post-test and survey.
  5. Click Process Credit.
  6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

 

Original Course Date: May 01, 2019

Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Melanoma module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of melanoma. The module also includes case studies on immunotherapy for the treatment of melanoma.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Elizabeth Buchbinder, MD

    Instructor, Medicine, Dana-Farber Cancer Institute

    Dana-Farber Cancer Institute

     

    Educational Objectives

    After completing this activity, the participant should be better able to:

    • Describe the rationale for common approaches to cancer immunotherapy in treatment of melanoma patients
    • Identify the appropriate clinical management of common side effects of immunotherapy agents
    • Implement cancer immunotherapy treatments for melanoma
    • Describe clinical efficacy of approved immunotherapies
    • Recognize patient selection criteria for different immunotherapies
    • Identify factors influencing dosing and choice of immunotherapy relative to other therapies for melanoma

     


    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-729-H01-P) 

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.6 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Elizabeth Buchbinder, MD: Consulting Fees - Array Pharmaceuticals; Salary - Sanofi


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

     

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.60 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse Adjuvant Therapy in Melanoma: What Is It and Is It Right For Me?

    Access Course

    This article is for people who want to understand how biomarkers may affect their cancer treatment choices. It's also for their care partners, and others who want to learn more about the topic. The goal is to help you know what to discuss with your healthcare team about testing for biomarkers and what the results mean for your treatment.

     

     

     

     

     

     

     

    You'll explore:

    • What adjuvant therapy in melanoma is
    • Who adjuvant therapy is recommended for
    • The potential benefits of adjuvant therapy
    • About side effects of adjuvant therapy
    • Questions to ask your provider about adjuvant therapy

     

    Available beginning: Dec. 18, 2018

     

    Approximate Time to Complete: 30 minutes

     

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018
    MORE INFOMORE INFO Adjuvant Therapy in Melanoma: What Is It and Is It Right For Me?
    Collapse From Adjuvant to Metastatic in Melanoma: What Should You Know?

    Access Course

     

    From Adjuvant to Metastatic in Melanoma: What Should You Know?Experts discuss the role of immunotherapy in the treatment of patients with melanoma across the disease settings.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

     

    The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 24, 2018 - Dec. 24, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 17, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.50 hours CEU

  • MORE INFOMORE INFO From Adjuvant to Metastatic in Melanoma: What Should You Know?
    Collapse Melanoma: Steps to Optimizing Clinical Outcomes

    Access Course

    Explore the latest in melanoma care through 2 cases, one in the adjuvant setting and one in the metastatic setting.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with melanoma.

     

     

     

     

    Credit Available: Feb. 25, 2019 - Feb. 25, 2020

     

    Approximate Time to Complete: 75 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 25, 2019
    MORE INFOMORE INFO Melanoma: Steps to Optimizing Clinical Outcomes